FDA grants priority review for Sanofi’s venglustat NDA
If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated
Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.
The collaboration aims to accelerate hit identification for these companies through a fee-for-success approach. It will combine OpenBench’s AI-based discovery platform with Concept Life Sciences’ expertise in medicinal